Breast cancer prevention: present and future.
Increased risk of breast cancer may result from modifiable factors such as endogenous hormone levels, obesity, HRT, and non-lactation, or non-modifiable factors such as genetic susceptibility or increasing age. Those factors that are easiest to modify may have a limited impact on the totality of breast cancer. The Gail model, based on known factors may be useful for estimating life-time risk in some individuals. Tamoxifen prevention still remains contentious. In the NSABP-P1 study, there was a 49% reduction in risk of breast cancer in women given tamoxifen but in the Italian and Royal Marsden trials, no effect on breast cancer incidence was detected, possibly because of the different case-mix in these studies. Raloxifene, tested in the MORE trial reduced the incidence of breast cancer by 65%. The effect was restricted to ER positive tumours: no reduction in ER negative cancers was seen. Life-style factors such as diet, obesity, exercise, and age of first full term pregnancy and number of pregnancies have a mild to moderate impact on risk and so may have little effect on the incidence of breast cancer. Reduction of alcohol intake could lead to a modest reduction in the risk of breast cancer but possibly adversely affect other diseases. So far, studies of retinoids have not shown a benefit in terms of breast cancer risk reduction. Fat reduction and GnRH analogues reduce mammographic density but have not yet been shown to affect risk.
Salih
A K
AK
Department of Surgical Oncology, Guy's Hospital, London, UK
Fentiman
I S
IS
D001943:Breast Neoplasms / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000639:trends*; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000517:prevention & control; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D012307:Risk Factors; D013629:Tamoxifen / Q000627:therapeutic use
D004965:Estrogen Antagonists; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride